Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)
China
· Delayed Price · Currency is CNY 59.35
+0.50 (0.85%)
Apr 29, 2026, 3:00 PM CST
Xiamen Amoytop Biotech Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 1,014 | 1,031 | 827.6 | 555.45 | 287.02 | 181.2 | Upgrade
|
| Depreciation & Amortization | 122.24 | 122.24 | 75.36 | 58.69 | 48.07 | 43.15 | Upgrade
|
| Other Amortization | 23.9 | 23.9 | 18.08 | 9.53 | 2.3 | 1.18 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.99 | 0.99 | 0.03 | 0.87 | -0.03 | 1.8 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | 12.76 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -9.79 | -9.79 | -4.94 | -6.2 | -3.92 | -6.78 | Upgrade
|
| Provision & Write-off of Bad Debts | -0.05 | -0.05 | 3.72 | 0.35 | -1.41 | -2.34 | Upgrade
|
| Other Operating Activities | -52.9 | 1.82 | 0.48 | 1.72 | 0.59 | 1.58 | Upgrade
|
| Change in Accounts Receivable | -405.58 | -405.58 | -404.83 | -205.76 | -15.51 | -24.54 | Upgrade
|
| Change in Inventory | -164.06 | -164.06 | -76.53 | -57.29 | -13.24 | -16.87 | Upgrade
|
| Change in Accounts Payable | 88.48 | 88.48 | 0.45 | 153.19 | 61.89 | 63.92 | Upgrade
|
| Change in Other Net Operating Assets | 61.86 | 61.86 | 16.1 | - | - | - | Upgrade
|
| Operating Cash Flow | 657.02 | 729.38 | 430.63 | 512.1 | 363.16 | 234.78 | Upgrade
|
| Operating Cash Flow Growth | 17.60% | 69.37% | -15.91% | 41.01% | 54.68% | 153.52% | Upgrade
|
| Capital Expenditures | -271.3 | -256.14 | -251.35 | -288.46 | -219.17 | -190.93 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.73 | 0.75 | 0.03 | 0.04 | 0.11 | 0.34 | Upgrade
|
| Cash Acquisitions | -58.39 | -58.39 | - | - | - | - | Upgrade
|
| Investment in Securities | 137.05 | -186.54 | -57.29 | -17.35 | -70.34 | 78.66 | Upgrade
|
| Other Investing Activities | 9.22 | - | - | - | - | 0.09 | Upgrade
|
| Investing Cash Flow | -182.69 | -500.33 | -308.62 | -305.76 | -289.4 | -111.84 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | - | 10 | Upgrade
|
| Long-Term Debt Issued | - | 140.67 | - | - | - | - | Upgrade
|
| Total Debt Issued | 172.17 | 140.67 | - | - | - | 10 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | -10 | -18.92 | Upgrade
|
| Long-Term Debt Repaid | - | -9.39 | -6.23 | -6.26 | -7.69 | -4.61 | Upgrade
|
| Total Debt Repaid | -37.01 | -9.39 | -6.23 | -6.26 | -17.69 | -23.53 | Upgrade
|
| Net Debt Issued (Repaid) | 135.16 | 131.28 | -6.23 | -6.26 | -17.69 | -13.53 | Upgrade
|
| Issuance of Common Stock | 54.44 | 54.44 | - | - | - | - | Upgrade
|
| Common Dividends Paid | -253.34 | -252.87 | -166.79 | -86.65 | -40.68 | -20.68 | Upgrade
|
| Other Financing Activities | -1.37 | - | - | - | - | - | Upgrade
|
| Financing Cash Flow | -65.11 | -67.16 | -173.02 | -92.91 | -58.37 | -34.2 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.64 | -0.55 | -0.13 | -1.11 | 0.03 | -0.49 | Upgrade
|
| Net Cash Flow | 408.57 | 161.34 | -51.14 | 112.32 | 15.42 | 88.25 | Upgrade
|
| Free Cash Flow | 385.72 | 473.23 | 179.28 | 223.64 | 143.99 | 43.85 | Upgrade
|
| Free Cash Flow Growth | 18.30% | 163.96% | -19.84% | 55.31% | 228.34% | - | Upgrade
|
| Free Cash Flow Margin | 10.10% | 12.80% | 6.36% | 10.65% | 9.43% | 3.87% | Upgrade
|
| Free Cash Flow Per Share | 0.94 | 1.16 | 0.44 | 0.55 | 0.36 | 0.11 | Upgrade
|
| Cash Income Tax Paid | 344.12 | 262.66 | 228.82 | 168.12 | 112.85 | 71.33 | Upgrade
|
| Levered Free Cash Flow | 293.18 | 390.68 | -44.25 | 41.08 | 127.17 | 11.47 | Upgrade
|
| Unlevered Free Cash Flow | 294.07 | 391.57 | -43.96 | 41.4 | 127.56 | 12.14 | Upgrade
|
| Change in Working Capital | -440.97 | -440.97 | -489.7 | -121.08 | 30.53 | 14.99 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.